Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Simvastatin

FDA-approved product (tablet, oral), marketed as Flolipid, Simvastatin, Zocor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Simvastatin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Acute myocardial infarction
  • Cardiovascular disease
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
FDA pharmacologic class
HMG-CoA Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Simvastatin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Simvastatin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Anti-inflammatory Effects of Simvastatin

    NCT04638400 · start 2017-05-01

    Registered record
    Registry ID
    NCT04638400
    Conditions
    Inflammation; Atherosclerosis; Hypercholesterolemia
    Interventions
    Simvastatin 40mg; Ezetimibe 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-05-01
    Completion
    2021-11-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation; Atherosclerosis; Hypercholesterolemia
    InterventionSimvastatin 40mg; Ezetimibe 10mg
    PhasePhase 4
    Registry statusTerminated

  • Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

    NCT02252328 · start 2015-09

    Registered record
    Registry ID
    NCT02252328
    Conditions
    Uveitis
    Interventions
    Simvastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2015-09
    Completion
    2019-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis
    InterventionSimvastatin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

    NCT02289963 · start 2015-01

    Registered record
    Registry ID
    NCT02289963
    Conditions
    Hypercholesterolemia
    Interventions
    Placebo (for Alirocumab); Alirocumab; Lipid-Modifying Therapy (LMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-04
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionPlacebo (for Alirocumab); Alirocumab; Lipid-Modifying Therapy (LMT)
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

    NCT01972178 · start 2013-11

    Registered record
    Registry ID
    NCT01972178
    Conditions
    Dyslipidemia
    Interventions
    PRC-4016; Placebo; Statins
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-11
    Completion
    2014-08
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionPRC-4016; Placebo; Statins
    PhasePhase 2
    Registry statusTerminated

  • Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

    NCT01420549 · start 2013-03

    Registered record
    Registry ID
    NCT01420549
    Conditions
    Hypercholesterolemia; Dyslipidemia
    Interventions
    Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-11
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Dyslipidemia
    InterventionRosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    PhasePhase 3
    Registry statusCompleted

  • Statin Recapture Therapy Before Coronary Artery Bypass Grafting

    NCT01715714 · start 2012-11-07

    Registered record
    Registry ID
    NCT01715714
    Conditions
    Coronary Artery Disease
    Interventions
    Statin Recapture Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11-07
    Completion
    2020-09-27
    Enrolment
    2,630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionStatin Recapture Therapy; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

    NCT01725230 · start 2012-11

    Registered record
    Registry ID
    NCT01725230
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib; Rosuvastatin; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib; Rosuvastatin; Simvastatin
    PhasePhase 1
    Registry statusCompleted

  • Single Pill to Avert Cardiovascular Events

    NCT01313702 · start 2012-10

    Registered record
    Registry ID
    NCT01313702
    Conditions
    Cardiovascular Disease
    Interventions
    polipillV1; polipillV2; usual care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-10
    Completion
    2014-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionpolipillV1; polipillV2; usual care
    PhasePhase 3
    Registry statusWithdrawn

  • The International Polycap Study 3 (TIPS-3)

    NCT01646437 · start 2012-06

    Registered record
    Registry ID
    NCT01646437
    Conditions
    Cardiovascular Disease; Fractures; Cancers
    Interventions
    Polycap; Aspirin; Vitamin D; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2021-08-30
    Enrolment
    7,793

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease; Fractures; Cancers
    InterventionPolycap; Aspirin; Vitamin D; Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

    NCT01674712 · start 2012-06

    Registered record
    Registry ID
    NCT01674712
    Conditions
    Dyslipidemia
    Interventions
    Fixed Combination of Fenofibrate/simvastatin 145/20 mg; Simvastatin 20 mg; Fenofibrate 145 mg; Fixed Combination of Fenofibrate/simvastatin 145/40 mg; Simvastatin 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-10
    Enrolment
    575

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionFixed Combination of Fenofibrate/simvastatin 145/20 mg; Simvastatin 20 mg; Fenofibrate 145 mg; Fixed Combination of Fenofibrate/simvastatin 145/40 mg +1 more
    PhasePhase 3
    Registry statusCompleted

  • Genetic Influence on Statin Pharmacodynamics

    NCT01569854 · start 2012-03

    Registered record
    Registry ID
    NCT01569854
    Conditions
    Hyperlipidemia; Hypercholesterolemia; Dyslipidemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2012-03
    Completion
    2022-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; Hypercholesterolemia; Dyslipidemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

    NCT01441349 · start 2011-08

    Registered record
    Registry ID
    NCT01441349
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    IP chemotherapy; IP chemotherapy plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2022-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionIP chemotherapy; IP chemotherapy plus simvastatin
    PhasePhase 2
    Registry statusUnknown

  • Effect of Cilostazol on the Pharmacokinetics of Simvastatin

    NCT01383395 · start 2011-06

    Registered record
    Registry ID
    NCT01383395
    Conditions
    Healthy
    Interventions
    simvastatin/cilostazol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionsimvastatin/cilostazol
    PhasePhase 1
    Registry statusCompleted

  • Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

    NCT01238094 · start 2010-04

    Registered record
    Registry ID
    NCT01238094
    Conditions
    Colorectal Cancer
    Interventions
    Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2014-05
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSimvastatin
    PhasePhase 3
    Registry statusUnknown

  • Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

    NCT01096940 · start 2010-03

    Registered record
    Registry ID
    NCT01096940
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    AZD1656; simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionAZD1656; simvastatin
    PhasePhase 1
    Registry statusCompleted